All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @doctadilf on TikTok · 53s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @doctadilf's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Here's my two month TRT blood work update.
  2. 0:02The good, the bad, and what I'm gonna fix.
  3. 0:05So before I started TRT,
  4. 0:07my total test was about 590,
  5. 0:09and my free test was 24.
  6. 0:11Two months in, my total test is about 1585,
  7. 0:14and my free T's 377.
  8. 0:16And yeah, I feel it.
  9. 0:17Energy's up, strength is up, recovery's up.
  10. 0:20But here's the part people don't talk about.
  11. 0:23My hemoglobin and hematocrit are high.
  12. 0:25Not insane, but they're high.
  13. 0:28So I'm not just gonna ignore that.
  14. 0:30I'm drinking more water, I'm up in my cardio,
  15. 0:32I'm gonna donate blood, and I'm gonna lower my dose.
  16. 0:35My HDL dropped a bit too, which is normal on TRT,
  17. 0:38but I did quit vaping, I'm gonna cut back on weed,
  18. 0:41and I'm really gonna focus on sleep.
  19. 0:44The point is, if you're gonna optimize,
  20. 0:46you actually need to optimize.
  21. 0:48Don't just track numbers and ego.
  22. 0:50Track it, adjust it, and be smart.

Two months on TRT: separating real progress from bro-science

Dylan Clarke

TikTok creator

8.0K viewsWatch on TikTok

Quick answer

The creator is running supraphysiological testosterone levels (1585 ng/dL total, 377 pg/mL free) after two months on TRT, starting from a baseline that does not meet standard clinical hypogonadism criteria (pre-TRT total T of 590 ng/dL). The elevated hematocrit and reduced HDL they describe are expected pharmacological effects of exogenous testosterone at this exposure level, and their plan to reduce dose and donate blood aligns with Endocrine Society management guidance, though both interventions should involve a prescribing clinician. Unresolved questions include the actual hematocrit value, the current dose, and whether cardiovascular risk has been formally assessed given the lipid changes.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Two months on TRT: separating real progress from bro-science, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Two months on TRT: separating real progress from bro-science is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Two months on TRT: separating real progress from bro-science" from Dylan Clarke. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is running supraphysiological testosterone levels (1585 ng/dL total, 377 pg/mL free) after two months on TRT, starting from a baseline that does not meet standard clinical hypogonadism criteria (pre-TRT total T of 590 ng/dL).

The reason this review is not generic is the source wording and the canonical claim label "trt 2 month trt update the good what i m fixing optimize don t e." In this clip, the useful excerpt is: "Here's my two month TRT blood work update." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Post-TRT total testosterone of 1585 ng/dL exceeds the upper physiological reference range (typically under 1000 ng/dL), placing this in enhancement territory rather than replacement, with corresponding higher risk of hematocrit elevation and lipid changes.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is running supraphysiological testosterone levels (1585 ng/dL total, 377 pg/mL free) after two months on TRT, starting from a baseline that does not meet standard clinical hypogonadism criteria (pre-TRT total T of 590 ng/dL).

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is running supraphysiological testosterone levels (1585 ng/dL total, 377 pg/mL free) after two months on TRT, starting from a baseline that does not meet standard clinical hypogonadism criteria (pre-TRT total T of 590 ng/dL). The elevated hematocrit and reduced HDL they describe are expected pharmacological effects of exogenous testosterone at this exposure level, and their plan to reduce dose and donate blood aligns with Endocrine Society management guidance, though both interventions should involve a prescribing clinician. Unresolved questions include the actual hematocrit value, the current dose, and whether cardiovascular risk has been formally assessed given the lipid changes.
  • A pre-TRT total testosterone of 590 ng/dL does not meet the standard clinical definition of hypogonadism, which most guidelines set below 300 ng/dL (Bhasin et al., 2018, JCEM). This matters for how you frame risk versus benefit.
  • Post-TRT total testosterone of 1585 ng/dL exceeds the upper physiological reference range (typically under 1000 ng/dL), placing this in enhancement territory rather than replacement, with corresponding higher risk of hematocrit elevation and lipid changes.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • A pre-TRT total testosterone of 590 ng/dL does not meet the standard clinical definition of hypogonadism, which most guidelines set below 300 ng/dL (Bhasin et al., 2018, JCEM). This matters for how you frame risk versus benefit.
  • Post-TRT total testosterone of 1585 ng/dL exceeds the upper physiological reference range (typically under 1000 ng/dL), placing this in enhancement territory rather than replacement, with corresponding higher risk of hematocrit elevation and lipid changes.
  • Erythrocytosis occurs in roughly 11-18% of men on TRT and is dose-dependent. Hematocrit above 52-54% raises cardiovascular risk through increased blood viscosity. The specific value matters and was not disclosed in this video.
  • Therapeutic blood donation is a legitimate management strategy for TRT-related erythrocytosis, but should be disclosed to and coordinated with a prescribing clinician, not done unilaterally.
  • HDL reduction on TRT is pharmacologically expected but not automatically benign. The absolute drop and baseline cardiovascular risk profile determine whether it requires active intervention beyond lifestyle changes.
  • Free testosterone of 377 pg/mL post-TRT is well above the physiological range and is the fraction most responsible for androgenic effects, including red blood cell stimulation and potential lipid changes.
  • Quitting nicotine products is independently beneficial for HDL regardless of TRT status. Craig et al. (1989, Arteriosclerosis) documented this relationship clearly, and it is one of the more evidence-backed lifestyle moves the creator mentioned.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @doctadilf actually say?

Pretty straightforward stuff, actually. The creator reported jumping from a pre-TRT total testosterone of 590 ng/dL and free testosterone of 24 pg/mL to 1585 ng/dL total and 377 pg/mL free after two months. They felt better, which tracks. But they also flagged elevated hemoglobin and hematocrit, a drop in HDL cholesterol, and outlined a plan: more water, more cardio, blood donation, and a dose reduction. They also mentioned quitting vaping and cutting back on cannabis to help their lipid profile.

This is not your typical TRT hype video. The creator explicitly said "don't just track numbers and ego" and framed the whole thing around adjustment rather than bragging. That matters when you're evaluating what they actually claimed versus what the comment section probably wanted to hear.

Does the science back this up?

Mostly, yes. The physiology they're describing is well-documented, and their planned interventions are reasonable, if incomplete.

Elevated hematocrit is one of the most consistently observed side effects of exogenous testosterone. A 2017 review by Bachman et al. in the Journal of Clinical Endocrinology and Metabolism confirmed that erythrocytosis (hematocrit above 54%) occurs in roughly 11-18% of men on TRT, driven by testosterone stimulating erythropoietin production. The creator's plan to donate blood is actually a clinically recognized management strategy, though it should be done in consultation with a prescribing physician, not just volunteered at a blood bank without disclosure.

The HDL drop also checks out. A 2013 meta-analysis by Corona et al. in the European Journal of Endocrinology found that testosterone therapy consistently reduces HDL cholesterol, with effect sizes varying by formulation and dose. Their plan to quit vaping and improve sleep are genuinely relevant here. Smoking and nicotine products independently suppress HDL, and sleep deprivation disrupts lipid metabolism.

What did they get wrong (or right)?

They got the biology right. Where things get murkier is the dose context and what "high" actually means for hematocrit.

The creator's total testosterone of 1585 ng/dL is above the upper limit of most laboratory reference ranges (typically 916-1000 ng/dL depending on the lab). Running supraphysiological levels isn't necessarily dangerous in the short term, but it is not "optimization" in any clinical sense. It's closer to enhancement. The creator seems to recognize this, which is why they're lowering the dose, but they don't name the number. That's a gap. Viewers watching this don't know if they're on 100 mg/week or 250 mg/week, and that context is genuinely important for anyone trying to apply this to their own situation.

On the hematocrit front, they said it's "not insane, but high." Without sharing the actual number, that's hard to evaluate. Hematocrit above 52% is where most guidelines, including those from the Endocrine Society, flag increased cardiovascular risk due to blood viscosity. Drinking more water and doing cardio help marginally. Blood donation is more meaningful. But the actual threshold matters, and omitting it is a miss.

Credit where it's due: recommending a dose reduction rather than doubling down is genuinely responsible messaging for this space.

What should you actually know?

A few things worth understanding before you interpret your own bloodwork through this lens.

First, pre-TRT total testosterone of 590 ng/dL is not low by standard clinical definitions. Most guidelines define hypogonadism below 300 ng/dL (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism). That doesn't mean someone at 590 ng/dL can't have symptoms or benefit from treatment, but it does mean this is firmly in "optimization" territory, not replacement therapy in the traditional sense. That's a meaningful distinction from a risk-benefit standpoint.

Second, free testosterone of 24 pg/mL pre-TRT is actually on the higher end of normal for most adult men under 50. The creator's post-TRT free T of 377 pg/mL is well above physiological range. Free testosterone drives most of the androgenic effects, including on red blood cell production and potentially on cardiovascular markers.

Third, HDL reduction on TRT is real and the magnitude matters. A drop of 5-10% is common. A drop of 20-30% paired with other cardiovascular risk factors is a different conversation. If you're on TRT and your HDL is dropping, you need your full lipid panel reviewed by someone who can assess your actual cardiovascular risk, not just the isolated number.

Bottom line: responsible messaging, incomplete data

The creator is doing more right than wrong here. They're monitoring bloodwork, acknowledging adverse changes, and adjusting behavior. That's better than most TRT content on this platform. But the missing numbers, including the actual hematocrit value and the testosterone dose, limit how useful this is for anyone watching. "High but not insane" is not a data point. Share the number or don't make the video about the numbers.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dylan Clarke · TikTok creator

8.0K views on this video

2 month TRT update. The good + what I’m fixing. Optimize. Don’t ego lift your hormones. #trt #testosterone #menshealth #bloodwork #hormoneoptimization

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about a pre-trt total testosterone of 590 ng/dl does not meet?

A pre-TRT total testosterone of 590 ng/dL does not meet the standard clinical definition of hypogonadism, which most guidelines set below 300 ng/dL (Bhasin et al., 2018, JCEM). This matters for how you frame risk versus benefit.

What does the video say about post-trt total testosterone of 1585 ng/dl exceeds the upper physiological?

Post-TRT total testosterone of 1585 ng/dL exceeds the upper physiological reference range (typically under 1000 ng/dL), placing this in enhancement territory rather than replacement, with corresponding higher risk of hematocrit elevation and lipid changes.

What does the video say about erythrocytosis occurs in roughly 11-18% of men on trt?

Erythrocytosis occurs in roughly 11-18% of men on TRT and is dose-dependent. Hematocrit above 52-54% raises cardiovascular risk through increased blood viscosity. The specific value matters and was not disclosed in this video.

What does the video say about therapeutic blood donation?

Therapeutic blood donation is a legitimate management strategy for TRT-related erythrocytosis, but should be disclosed to and coordinated with a prescribing clinician, not done unilaterally.

What does the video say about hdl reduction on trt?

HDL reduction on TRT is pharmacologically expected but not automatically benign. The absolute drop and baseline cardiovascular risk profile determine whether it requires active intervention beyond lifestyle changes.

What does the video say about free testosterone of 377 pg/ml post-trt?

Free testosterone of 377 pg/mL post-TRT is well above the physiological range and is the fraction most responsible for androgenic effects, including red blood cell stimulation and potential lipid changes.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dylan Clarke, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.